Tango Therapeutics (TNGX) investor relations material

Executive summary

• Advanced vopimetostat and TNG456 in targeted oncology, focusing on MTAP-deleted selective PRMT5 inhibitors, with ongoing and planned clinical trials in combination with RAS inhibitors and as monotherapies; pivotal trial strategy for vopimetostat in pancreatic cancer to be detailed in 2026.

• Deprioritized TNG260 and TNG961 programs to concentrate resources on PRMT5 pipeline; TNG908 trial stopped due to insufficient brain exposure and reduced development costs.

• Strengthened leadership team with new CFO, Chief Development Operations Officer, and SVP of Corporate Strategy; two board resignations as company accelerates late-stage development.

• No products approved or revenue from product sales; operations funded by equity and collaboration agreements.

Financial highlights

• Net loss for Q1 2026 was $45.5 million ($0.32 per share), compared to $39.9 million ($0.36 per share) in Q1 2025.

• No collaboration revenue recognized in Q1 2026, versus $5.4 million in Q1 2025, due to the conclusion of the Gilead research collaboration.

• Research and development expenses decreased to $33.5 million from $36.4 million year-over-year, mainly due to program discontinuations and lower costs.

• General and administrative expenses increased to $15.2 million from $11.5 million, driven by higher personnel and stock-based compensation.

• Cash, cash equivalents, and marketable securities totaled $379.8 million as of March 31, 2026, expected to fund operations into 2028.

Outlook and guidance

• Existing cash and equivalents expected to fund operations into 2028.

• Initial phase 1/2 safety and efficacy data from vopimetostat + RAS(ON) inhibitor combinations, monotherapy vopimetostat in lung cancer, and TNG456 in glioblastoma anticipated in 2026.

• Phase 1/2 vopimetostat + ERAS-0015 combination study to initiate in the second half of 2026.

• Anticipates continued operating losses and negative cash flow as clinical programs advance.